Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4729458 | 0.82 | TRPV4 (0.37) | TRPV4GRM5ALDH1A1APLNRGPR119 | |
| SCHEMBL17586504 | 0.80 | TRPV4 (0.40) | TRPV4GRM5ALDH1A1APLNRGPR119 | |
| SCHEMBL29649716 | 0.80 | TRPV4 (0.40) | TRPV4GRM5ALDH1A1APLNRGPR119 | |
| SCHEMBL16019424 | 0.78 | TRPV4 (0.34) | TRPV4GRM5ALDH1A1APLNRGPR119 | |
| SCHEMBL1507186 | 0.78 | PDE10A (0.43) | TRPV4APLNRPDE10APTGS2HSD11B1 | |
| SCHEMBL23262834 | 0.78 | GRM5 (0.35) | TRPV4GRM5ALDH1A1APLNRGPR119 | |
| SCHEMBL18463843 | 0.78 | TRPV4 (0.34) | TRPV4GRM5ALDH1A1APLNRGPR119 | |
| SCHEMBL16132531 | 0.78 | HSD11B1 (0.37) | TRPV4APLNRPDE10APTGS2HSD11B1 | |
| SCHEMBL2568687 | 0.75 | GRM5 (0.33) | TRPV4GRM5ALDH1A1APLNR | |
| SCHEMBL22601556 | 0.75 | CA12 (0.35) | TRPV4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | TRPV4 4721/4885GRM5 4768/4885ALDH1A1 1908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.